Yuli Y. Kim

Yuli Y. Kim

Auto-generated profile, based on publicly available information

Yuli Y. Kim

Children's Hospital of Philadelphia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
LDLisa X. Deng
Lisa X. Deng
AKAbigail May Khan
Abigail May Khan
DDDavid Drajpuch
David Drajpuch
SFStephanie Fuller
Stephanie Fuller
JLJonathan Ludmir
Jonathan Ludmir
YKYuli Y. Kim
Yuli Y. Kim

1 November 2015 in Cardiology Clinics
Verified
Journal Article
Closed access
TDTacy E. Downing
Tacy E. Downing
YKYuli Y. Kim
Yuli Y. Kim

17 December 2016 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
BDBenjamin A. D'Souza
Benjamin A. D'Souza
SFStephanie Fuller
Stephanie Fuller
LGLacey P. Gleason
Lacey P. Gleason
NHNicole Hornsby
Nicole Hornsby
JWJoyce Wald
Joyce Wald
YKYuli Y. Kim
Yuli Y. Kim

1 August 2020 in Cardiology Clinics
Verified
Journal Article
Closed access
YKYuli Y. Kim
Yuli Y. Kim
LALauren Andrade
Lauren Andrade
SCStephen C. Cook
Stephen C. Cook

23 December 2020 in Heart
Verified
Journal Article
Closed access
PDF file
DBDanielle S Burstein
Danielle S Burstein
JRJoseph W Rossano
Joseph W Rossano
HGHeather Griffis
Heather Griffis
XZXuemei Zhang
Xuemei Zhang
RFRachel Fowler
Rachel Fowler
JMJonathan N Menachem
Jonathan N Menachem
Objective Limited contemporary data exist regarding outcomes and resource use among adults with congenital heart disease and heart failure (ACHD-HF). This study compared outcomes, emergency department (ED) and hospital resource use, and advanced heart failure (HF) therapies in ACHD-HF versus non-ACHD with HF (HF-non-ACHD). Methods The Nationwide Emergency Department Sample and Nationwide Inpatient Sample were used to analyse outcomes and resource use among ACHD-HF ED visits and hospitalisations from 2006 to 2016. ACHD-HF was stratified by single-ventricle (SV) and two-ventricle (2V) disease. Results A total of 76 557 ACHD-HF visits (3.6% SV physiology) and 31 137 414 HF-non-ACHD visits were analysed. ACHD-HFs were younger (SV 33 years (IQR 25–44), 2V 62 years (IQR 45–76); HF-non-ACHD 74 years (IQR 63–83); p<0.001). ACHD-HFs had higher ED admissions (78% vs 70%, p<0.001), longer hospital length of stay (5 days (IQR 2–8) vs 4 days (IQR 2–7), p<0.001) and greater hospital costs ($49K (IQR 2K–121K) vs $32K (17K–66K), p<0.001). Mortality was significantly higher among ACHD-HFs with SV physiology (6.6%; OR 1.6, 95% CI 1.1 to 2.3) or 2V physiology (6.3%; OR 1.4, 95% CI 1.3 to 1.5) versus HF-non-ACHD (5.5%). ACHF-HF hospitalisations increased more (46% vs 6% HF-non-ACHD) over a 10-year period, but the proportion receiving ventricular assist device (VAD) (ACHD-HF −2% vs HF-non-ACHD 294%) or transplant (ACHD-HF −37% vs HF-non-ACHD 73%) decreased. Conclusion ACHD-HFs have significant ED and hospital resource use that has increased over the past 10 years. However, advanced HF therapies (VAD and transplantation) are less commonly used compared with those without adult congenital heart disease.

3 January 2019 in Congenital Heart Disease
Verified
Journal Article
Closed access
PDF file
YKYuli Y. Kim
Yuli Y. Kim
LGLeah A. Goldberg
Leah A. Goldberg
KAKatherine Awh
Katherine Awh
TBTanmay Bhamare
Tanmay Bhamare
DDDavid Drajpuch
David Drajpuch
LLLisa D. Levine
Lisa D. Levine
Objective To assess performance of risk stratification schemes in predicting adverse cardiac outcomes in pregnant women with congenital heart disease (CHD) and to compare these schemes to clinical factors alone. Design Single‐center retrospective study. Setting Tertiary care academic hospital. Patients Women ≥18 years with International Classification of Diseases, Ninth Revision, Clinical Modification codes indicating CHD who delivered between 1998 and 2014. CARPREG I and ZAHARA risk scores and modified World Health Organization (WHO) criteria were applied to each woman. Outcome Measures The primary outcome was defined by ≥1 of the following: arrhythmia, heart failure/pulmonary edema, transient ischemic attack, stroke, dissection, myocardial infarction, cardiac arrest, death during gestation and up to 6 months postpartum. Results Of 178 women, the most common CHD lesions were congenital aortic stenosis (15.2%), ventricular septal defect (13.5%), atrial septal defect (12.9%), and tetralogy of Fallot (12.9%). Thirty‐five women (19.7%) sustained 39 cardiac events. Observed vs expected event rates were 9.9% vs 5% (P = .02) for CARPREG I score 0 and 26.1% vs 7.5% (P < .001) for ZAHARA scores 0.51‐1.5. ZAHARA outperformed CARPREG I at predicting adverse cardiovascular outcomes (AUC 0.80 vs 0.72, P = .03) but was not significantly better than modified WHO. Clinical predictors of adverse cardiac event were symptoms (P = .002), systemic ventricular dysfunction (P < .001), and subpulmonary ventricular dysfunction (P = .03) with an AUC 0.83 comparable to ZAHARA (P = .66). Conclusions CARPREG I and ZAHARA scores underestimate cardiac risk for lower risk pregnancies in these women. Of the three risk schemes, CARPREG I performed least well in predictive capacity. Clinical factors specific to the population studied are comparable to stratification schemes.